TY  - GEN
AU  - Müller,M C
AU  - Gattermann,N
AU  - Lahaye,T
AU  - Deininger,M W N
AU  - Berndt,A
AU  - Fruehauf,S
AU  - Neubauer,A
AU  - Fischer,T
AU  - Hossfeld,D K
AU  - Schneller,F
AU  - Krause,S W
AU  - Nerl,C
AU  - Sayer,H G
AU  - Ottmann,O G
AU  - Waller,C
AU  - Aulitzky,W
AU  - le Coutre,P
AU  - Freund,M
AU  - Merx,K
AU  - Paschka,P
AU  - König,H
AU  - Kreil,S
AU  - Berger,U
AU  - Gschaidmeier,H
AU  - Hehlmann,R
AU  - Hochhaus,A
TI  - Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
SN  - 0887-6924
PY  - 2004///0123
KW  - Adult
KW  - Aged
KW  - Antimetabolites, Antineoplastic
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - Benzamides
KW  - Cross-Over Studies
KW  - Cytarabine
KW  - Cytogenetics
KW  - Female
KW  - Fusion Proteins, bcr-abl
KW  - genetics
KW  - Humans
KW  - Imatinib Mesylate
KW  - Interferon-alpha
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - diagnosis
KW  - Male
KW  - Middle Aged
KW  - Piperazines
KW  - Prognosis
KW  - Prospective Studies
KW  - Pyrimidines
KW  - RNA, Messenger
KW  - metabolism
KW  - Recurrence
KW  - Risk Factors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/sj.leu.2403157
ER  -